Good_老虎社区_美港股上老虎

2021-07-13

Good

You Should Know About Monday's 2 Big Nasdaq Winners

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":142183539,"tweetId":"142183539","gmtCreate":1626136523021,"gmtModify":1633929816602,"author":{"id":3582660441215591,"idStr":"3582660441215591","authorId":3582660441215591,"authorIdStr":"3582660441215591","name":"Magdalene89","avatar":"https://static.tigerbbs.com/ebb4c866593af8c808394f620f5b7d43","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":14,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Good</p></body></html>","htmlText":"<html><head></head><body><p>Good</p></body></html>","text":"Good","highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/142183539","repostId":1198299202,"repostType":4,"repost":{"id":"1198299202","kind":"news","pubTimestamp":1626136031,"share":"https://www.laohu8.com/m/news/1198299202?lang=&edition=full","pubTime":"2021-07-13 08:27","market":"us","language":"en","title":"You Should Know About Monday's 2 Big Nasdaq Winners","url":"https://stock-news.laohu8.com/highlight/detail?id=1198299202","media":"Motley Fool","summary":"One's a well-known name, while the other has plenty of potential.\n\nKey Points\n\nMarkets were generall","content":"<blockquote>\n One's a well-known name, while the other has plenty of potential.\n</blockquote>\n<p><b>Key Points</b></p>\n<ul>\n <li>Markets were generally higher on Monday.</li>\n <li>One stock rose on news about technological advances with its key products.</li>\n <li>Another stock released favorable study results in a clinical trial.</li>\n</ul>\n<p>The Possible Demise of the iPhone</p>\n<p></p>\n<p>Stocks were largely higher on Monday after overcoming a slow start to the trading week. By 2:30 p.m. EDT, the<b>Nasdaq Composite</b>(NASDAQINDEX:^IXIC)had climbed about 0.2%, with aspirations to finish at an all-time high.</p>\n<p>A couple of stocks contributed significantly to the positive mood on Wall Street.<b>Tesla</b>(NASDAQ:TSLA)is a perennial favorite among many investors, and its stock was among the best performers in the mega-cap arena. Meanwhile, tiny<b>Celldex Therapeutics</b>(NASDAQ:CLDX)enjoyed much larger gains that stemmed from good news about one of its candidate treatments. Below, we'll go into more detail about today's moves.</p>\n<p><b>Tesla gears up</b></p>\n<p>Shares of Tesla were higher by 4%. The stock overcame negative comments from one set of Wall Street analysts even as CEO Elon Musk gave testimony about Tesla's purchase of its SolarCity unit from several years back.</p>\n<p>One explanation for the optimism about the stock relates to Tesla's self-driving vehicle technology. The company started to enable vehicles whose owners paid in advance for incremental software updates toupgrade to the latest beta version of Tesla's autonomous driving software. Yet Tesla warned drivers not to assume too much about the driver assistance system, in an effort to avoid some of the accidents that have resulted from Tesla owners counting on their vehicles to do too much without any human intervention.</p>\n<p>Yet analysts at Citi were skeptical about the release, arguing that early indications suggest minimal improvement in features. Citi is among the most bearish analysts on Tesla, with a sell rating and a price target of $175 per share.</p>\n<p>Meanwhile, many shareholders are watching Musk's testimony in Delaware court, in which he's been asked to defend his role in Tesla's SolarCity acquisition. Naysayers have centered on family relationships between top-level executives at both companies. Cross-examination, however, got heated and seemingly personal.</p>\n<p>Tesla's ability to move higher shows that shareholders are able to separate Musk's role from the future success of the company. That's a positive development and could support future gains for theelectric car stock.</p>\n<p><b>Celldex gets a win</b></p>\n<p>Elsewhere, shares of Celldex Therapeutics moved higher by 23%. The little-known biotech got an early win with a key candidate treatment in its development pipeline.</p>\n<p>Celldex released positive data late Fridayon its CDX-0159 candidate treatment, which aims to help patients who are dealing with chronic urticaria, another name for hives. The phase 1b study involved 19 patients, and all but one of them had a complete response that included depletion of skin mast cells.</p>\n<p>Obviously, it's still early in the clinical trial process, but CEO Anthony Marucci was still optimistic about the results. The Celldex leader believes that the news points to a higher probability that CDX-0159 could help patients with other related diseases as well, and he's hopeful that the treatment's indications will expand over time.</p>\n<p>Celldex shares have quadrupled in price over the past year as investors have grown more optimistic about the company's monoclonal antibody biotechnology. If it can keep generating positive trial results, then Celldex could have a lot further to rise in the months and years ahead.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>You Should Know About Monday's 2 Big Nasdaq Winners</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nYou Should Know About Monday's 2 Big Nasdaq Winners\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-13 08:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/12/you-should-know-about-mondays-2-big-nasdaq-winners/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>One's a well-known name, while the other has plenty of potential.\n\nKey Points\n\nMarkets were generally higher on Monday.\nOne stock rose on news about technological advances with its key products.\n...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/12/you-should-know-about-mondays-2-big-nasdaq-winners/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉","CLDX":"塞德斯医疗"},"source_url":"https://www.fool.com/investing/2021/07/12/you-should-know-about-mondays-2-big-nasdaq-winners/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1198299202","content_text":"One's a well-known name, while the other has plenty of potential.\n\nKey Points\n\nMarkets were generally higher on Monday.\nOne stock rose on news about technological advances with its key products.\nAnother stock released favorable study results in a clinical trial.\n\nThe Possible Demise of the iPhone\n\nStocks were largely higher on Monday after overcoming a slow start to the trading week. By 2:30 p.m. EDT, theNasdaq Composite(NASDAQINDEX:^IXIC)had climbed about 0.2%, with aspirations to finish at an all-time high.\nA couple of stocks contributed significantly to the positive mood on Wall Street.Tesla(NASDAQ:TSLA)is a perennial favorite among many investors, and its stock was among the best performers in the mega-cap arena. Meanwhile, tinyCelldex Therapeutics(NASDAQ:CLDX)enjoyed much larger gains that stemmed from good news about one of its candidate treatments. Below, we'll go into more detail about today's moves.\nTesla gears up\nShares of Tesla were higher by 4%. The stock overcame negative comments from one set of Wall Street analysts even as CEO Elon Musk gave testimony about Tesla's purchase of its SolarCity unit from several years back.\nOne explanation for the optimism about the stock relates to Tesla's self-driving vehicle technology. The company started to enable vehicles whose owners paid in advance for incremental software updates toupgrade to the latest beta version of Tesla's autonomous driving software. Yet Tesla warned drivers not to assume too much about the driver assistance system, in an effort to avoid some of the accidents that have resulted from Tesla owners counting on their vehicles to do too much without any human intervention.\nYet analysts at Citi were skeptical about the release, arguing that early indications suggest minimal improvement in features. Citi is among the most bearish analysts on Tesla, with a sell rating and a price target of $175 per share.\nMeanwhile, many shareholders are watching Musk's testimony in Delaware court, in which he's been asked to defend his role in Tesla's SolarCity acquisition. Naysayers have centered on family relationships between top-level executives at both companies. Cross-examination, however, got heated and seemingly personal.\nTesla's ability to move higher shows that shareholders are able to separate Musk's role from the future success of the company. That's a positive development and could support future gains for theelectric car stock.\nCelldex gets a win\nElsewhere, shares of Celldex Therapeutics moved higher by 23%. The little-known biotech got an early win with a key candidate treatment in its development pipeline.\nCelldex released positive data late Fridayon its CDX-0159 candidate treatment, which aims to help patients who are dealing with chronic urticaria, another name for hives. The phase 1b study involved 19 patients, and all but one of them had a complete response that included depletion of skin mast cells.\nObviously, it's still early in the clinical trial process, but CEO Anthony Marucci was still optimistic about the results. The Celldex leader believes that the news points to a higher probability that CDX-0159 could help patients with other related diseases as well, and he's hopeful that the treatment's indications will expand over time.\nCelldex shares have quadrupled in price over the past year as investors have grown more optimistic about the company's monoclonal antibody biotechnology. If it can keep generating positive trial results, then Celldex could have a lot further to rise in the months and years ahead.","news_type":1},"isVote":1,"tweetType":1,"viewCount":24,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/142183539"}